Q-omics provides the consensus-scored ARGLU1 profile across patient tissues and cancer cell-line models. ARGLU1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ARGLU1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ARGLU1 protein abundance shows 38,191 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, KICH, and LUAD as cancer lineages where ARGLU1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARGLU1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARGLU1 survival associations across molecular data types. ARGLU1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARGLU1 RNA expression–survival associations across cancer types. High ARGLU1 expression shows unfavorable associations in ACC, KIRC and UVM, but favorable associations in BLCA, MESO and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ARGLU1 RNA expression.
This table summarizes ARGLU1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 12. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ARGLU1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARGLU1 shows lower tumor expression in KICH, LUAD, BRCA and UCEC and higher tumor expression in COAD and LIHC. The KICH box plot shows higher ARGLU1 RNA expression in normal versus tumor tissue (log2 FC = −1.864, t-test p < 0.001).
This table shows molecular features associated with ARGLU1 in patient tissues and cancer cell lines. In patient samples, ARGLU1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ARGLU1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
